MRI-based Radiomics for Predicting Prostate Cancer Grade Groups: A Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies.

RATIONALE AND OBJECTIVES

Prostate cancer (PCa) is the second most common cancer among men and a leading cause of cancer-related mortalities. Radiomics has shown promising performances in the classification of PCa grade group (GG) in several studies. Here, we aimed to systematically review and meta-analyze the performance of radiomics in predicting GG in PCa.

MATERIALS AND METHODS

Adhering to PRISMA-DTA guidelines, we included studies employing magnetic resonance imaging-derived radiomics for predicting GG, with histopathologic evaluations as the reference standard. Databases searched included Web of Sciences, PubMed, Scopus, and Embase. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) and METhodological RadiomICs Score (METRICS) tools were used for quality assessment. Pooled estimates for sensitivity, specificity, likelihood ratios, diagnostic odds ratio, and area under the curve (AUC) were calculated. Cochran's Q and I-squared tests assessed heterogeneity, while meta-regression, subgroup analysis, and sensitivity analysis addressed potential sources. Publication bias was evaluated using Deek's funnel plot, while clinical applicability was assessed with Fagan nomograms and likelihood ratio scattergrams.

RESULTS

Data were extracted from 43 studies involving 9983 patients. Radiomics models demonstrated high accuracy in predicting GG. Patient-based analyses yielded AUCs of 0.93 for GG≥2, 0.91 for GG≥3, and 0.93 for GG≥4. Lesion-based analyses showed AUCs of 0.84 for GG≥2 and 0.89 for GG≥3. Significant heterogeneity was observed, and meta-regression identified sources of heterogeneity. Radiomics model showed moderate power to exclude and confirm the GG.

CONCLUSION

Radiomics appears to be an accurate noninvasive tool for predicting PCa GG. It improves the performance of standard diagnostic methods, enhancing clinical decision-making.